期刊文献+

直接测序法检测结肠癌K-ras基因的灵敏度确认及评估 被引量:3

Sensitivity confirmation and assessment of the direct sequencing for the K-RAS gene in colorectal cancers
暂未订购
导出
摘要 目的探讨直接测序法检测K-ras基因的灵敏度及可行性。方法用已知K-ras基因突变型及野生型细胞株DNA按比例混合,用直接测序法检测K-ras基因突变情况,对实验敏感度进行评估。结果正反向测序结果均显示,含突变型K-ras基因DNA 5%的5个复孔中,均未能明确检出突变,而含突变型基因DNA≥10%的所有样本及其复孔都检测出了突变;突变型的基因碱基T峰与野生型的对应碱基G峰的比例,各组间有明显差异(P均<0.05),且峰高随突变型DNA的质量浓度增加而增加,二者存在明确相关性(相关系数r=-1.00,相伴概率<0.05)。结论直接测序法检测突变型DNA,当敏感度为10%时,特异性达到100%,且电泳图上突变峰与野生峰的高低比例可对细胞比例进行半定量评估,可以满足临床检测与研究。 Objective To investigate the sensitivity and feasibility of K-ras gene detected by direct sequencing.Methods Using the certified cell colons containing wild and mutant type K-ras gene,the gradient concentrations were got,the mutation of samples were tested by the direct sequencing method,the sensitivity of the experiment was estimated.Results Both the forword and reverse sequencing showed that each of the five tubes which had the 5% mutant DNA showed no K-ras mutation,and all the tubes which contain 10% mutant DNA showed K-ras mutation.The ratio of mutant base T and wild base G had statistic difference in every groups(all P〈0.05).The height of the mutant peak was increased with the concentration of the mutant DNA,there was definite correlation between them(r=-1.00,Sig.〈0.05).Conclusion Using the sensitivity of 10%,the specificity of DNA direct sequencing could reach 100%.The height of the mutant peak of the electrophoretogram could be used to half-quantify the concentration of the mutant DNA in the sample,and which was satisfactory for clinical test and study.
出处 《山东医药》 CAS 北大核心 2011年第11期31-33,共3页 Shandong Medical Journal
关键词 肠肿瘤 基因检测 直接测序法 灵敏度 colorectal cancer gene detection direct sequencing sensitivity
  • 相关文献

参考文献5

二级参考文献39

  • 1方福德.人类基因组研究20年[J].中国医药生物技术,2007,2(4):245-248. 被引量:1
  • 2方福德.与肿瘤个体化诊疗相关的科技计划[J].中华肿瘤杂志,2006,28(10):798-798. 被引量:6
  • 3Dulbecco R. A turning point in cancer research:sequencing the human genome [ J ]. Science, 1986,231 (4742) : 1055 - 1056.
  • 4Cabtor C. Orchestrating the human genome project[ J]. Science, 1990,248(4951 ) :49 -51.
  • 5Collins FS, Galas D. A new five - year plan for the U.S. Human genome project[ J]. Science, 1993,262(5130) :43 -46.
  • 6Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome[ J]. Nature,2001,409 (6822) :860- 921.
  • 7Ventei JC,Adams MD, Myers EW, et al. The sequence of the human genome [ J]. Science,2001,291 (5507) : 1304 - 1351.
  • 8C.丹尼斯,R.加拉格尔,J.D.沃森.人类基因组[M].北京:科学出版社,2003:4.
  • 9Colllins FS. Shattuck Lecture - Medical and societal consequences of the human genome project [ J ] . N Engl J Med, 1999,341:28-37.
  • 10Aitken N,Smith S,Schwarz C.2004.Single nucleotide polymorphism (SNP) discovery in mammals:a targeted-gene approach.Molecular Ecology,13:1423-1431.

共引文献21

同被引文献28

  • 1杨玲,李连弟,陈育德,D.M.Parkin.中国2000年及2005年恶性肿瘤发病死亡的估计与预测[J].中国卫生统计,2005,22(4):218-221. 被引量:337
  • 2Lin CC, Yang JC. Optimal management of patients with non-small eell lung cancer and epidermal growth faetor receptor mutations[J ]. Drugs, 2011,71 (1) : 79-88.
  • 3Armour AA,Watkins CL. The challenge of targeting EG- FR:experienee with gefitinib in nonsmall cell lung cancer [J]. Eur Respir Rev,2010,19(117);186 -196.
  • 4Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung eancer[J]. Nat Rev Cancer, 2007,7(3) : 169-181.
  • 5Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and elinieopathologie features [J]. Clin Cancer Res, 2006,12(5) : 1647-1653.
  • 6Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR mutations in lung cancer, a report from India[J]. Lung Cancer, 2011,73(3) :316-319.
  • 7Mitsudomi T,Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer[J]. Inl J Clin Oncol, 2006,11 (3) : 190-198.
  • 8Dacic S.Molecular diagnostics of lung carcinomas[J].Arch Pathol Lab Med,2011,135(5):622-629.
  • 9Wu YL,Kim JH,Park K,et al.Efficacy and safety of maintenance erlotinibin Asian patients with advanced non-small-cell lung cancer:A subanalysis of the phase III,randomized SATURN study[J].Lung Cancer,2012,77(2):339-345.
  • 10Billah S,Stewart J,Staerkel G,et al.EGFR and KRAS mutations in lung carcinoma:molecular testing by using cytology specimens[J].Cancer Cytopathol,2011,119(2):111-117.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部